Table 3—

HR by subgroups (diabetic patients only) for total cardiovascular events and procedures

Atorvastatin
Placebo
Unadjusted HR (95% CI)P value
n (%)Rate*n (%)Rate*
Age ≤60 years20 (4.7)14.934 (8.7)280.53 (0.31–0.92)0.022
Age >60 years96 (11.5)38.4117 (13.3)44.30.87 (0.66–1.14)0.300
Female sex26 (9.0)28.831 (10.0)31.90.90 (0.53–1.51)0.686
Male sex90 (9.3)30.6120 (12.5)41.60.74 (0.56–0.970.028
LDL <3.46 mmol/l56 (8.5)27.562 (9.1)29.30.93 (0.65–1.34)0.708
LDL ≥3.46 mmol/l53 (10.8)36.372 (15.5)52.90.69 (0.48–0.98)0.037
HDL <1.3 mmol/l67 (9.2)30.696 (12.7)42.70.72 (0.52–0.98)0.036
HDL ≥1.3 mmol/l49 (9.3)29.755 (10.6)34.10.87 (0.59–1.28)0.481
Triglycerides <1.4 mmol/l37 (8.7)28.255 (13.3)43.80.64 (0.42–0.97)0.036
Triglycerides ≥1.4 mmol/l72 (9.5)31.681 (10.6)35.10.90 (0.65–1.24)0.512
Glucose <5.6 mmol/l5 (6.0)19.48 (10.1)33.10.59 (0.19–1.81)0.354
Glucose ≥5.6 mmol/l104 (9.5)31.2128 (11.7)38.60.81 (0.62–1.05)0.105
All diabetic patients116 (9.2)30.2151 (11.9)39.10.77 (0.61–0.98)0.036
  • *

    * Rates are per 1,000 patient-years.